These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37979284)

  • 1. Initiation of warfarin is associated with decreased mortality in patients with infective endocarditis: A population-based cohort study.
    Lee TTL; Chan SCL; Chou OHI; Lee S; Chan JSK; Liu T; Chang C; Wong WT; Lip GYH; Cheung BMY; Wai AK; Tse G
    Thromb Res; 2024 Jan; 233():1-9. PubMed ID: 37979284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage.
    Tsai CT; Liao JN; Chiang CE; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chung FP; Chao TF; Lip GYH; Chen SA
    JAMA Netw Open; 2020 Jun; 3(6):e206424. PubMed ID: 32478848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Bleeding Following Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Acute Ischemic Stroke Treated With Alteplase.
    Tsai TY; Liu YC; Huang WT; Tu YK; Qiu SQ; Noor S; Huang YC; Chou EH; Lai EC; Huang HK
    JAMA Intern Med; 2024 Jan; 184(1):37-45. PubMed ID: 37983035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation.
    Graham DJ; Baro E; Zhang R; Liao J; Wernecke M; Reichman ME; Hu M; Illoh O; Wei Y; Goulding MR; Chillarige Y; Southworth MR; MaCurdy TE; Kelman JA
    Am J Med; 2019 May; 132(5):596-604.e11. PubMed ID: 30639551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aortic Stenosis and Outcomes in Patients With Atrial Fibrillation: A Nationwide Cohort Study.
    Teppo K; Airaksinen KEJ; Biancari F; Jaakkola J; Halminen O; Linna M; Haukka J; Putaala J; Mustonen P; Kinnunen J; Luojus A; Hartikainen J; Aro AL; Lehto M
    J Am Heart Assoc; 2023 May; 12(9):e029337. PubMed ID: 37119067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
    Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
    Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex-Based Differences in Outcomes of Oral Anticoagulation in Patients With Atrial Fibrillation.
    Law SWY; Lau WCY; Wong ICK; Lip GYH; Mok MT; Siu CW; Chan EW
    J Am Coll Cardiol; 2018 Jul; 72(3):271-282. PubMed ID: 30012320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of suboptimal anticoagulation treatment with antiplatelet therapy and warfarin on clinical outcomes in patients with nonvalvular atrial fibrillation: A population-wide cohort study.
    Chan EW; Lau WC; Siu CW; Lip GY; Leung WK; Anand S; Man KK; Wong IC
    Heart Rhythm; 2016 Aug; 13(8):1581-8. PubMed ID: 27033342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits and risks of anticoagulation resumption following traumatic brain injury.
    Albrecht JS; Liu X; Baumgarten M; Langenberg P; Rattinger GB; Smith GS; Gambert SR; Gottlieb SS; Zuckerman IH
    JAMA Intern Med; 2014 Aug; 174(8):1244-51. PubMed ID: 24915005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban Versus Warfarin in African American Patients with Nonvalvular Atrial Fibrillation.
    Coleman CI; Thompson S; Ashton V; Palladino M; Bunz TJ
    J Natl Med Assoc; 2020 Aug; 112(4):395-401. PubMed ID: 32493618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation.
    Chan YH; Kuo CT; Yeh YH; Chang SH; Wu LS; Lee HF; Tu HT; See LC
    J Am Coll Cardiol; 2016 Sep; 68(13):1389-1401. PubMed ID: 27659460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation.
    Winkelmayer WC; Liu J; Setoguchi S; Choudhry NK
    Clin J Am Soc Nephrol; 2011 Nov; 6(11):2662-8. PubMed ID: 21959598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular, Bleeding, and Mortality Risks of Dabigatran in Asians With Nonvalvular Atrial Fibrillation.
    Chan YH; Yen KC; See LC; Chang SH; Wu LS; Lee HF; Tu HT; Yeh YH; Kuo CT
    Stroke; 2016 Feb; 47(2):441-9. PubMed ID: 26732563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and Safety of Dabigatran in Atrial Fibrillation Patients with Severe Obesity: a Real-World Retrospective Cohort Study.
    Huang CW; Duan L; An J; Sim JJ; Lee MS
    J Gen Intern Med; 2022 Sep; 37(12):2982-2990. PubMed ID: 34545470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
    Graham DJ; Reichman ME; Wernecke M; Zhang R; Southworth MR; Levenson M; Sheu TC; Mott K; Goulding MR; Houstoun M; MaCurdy TE; Worrall C; Kelman JA
    Circulation; 2015 Jan; 131(2):157-64. PubMed ID: 25359164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ISCHEMIC STROKE AND MAJOR BLEEDING WHILE ON DIRECT ORAL ANTICOAGULANTS IN NAÏVE PATIENTS WITH ATRIAL FIBRILLATION: IMPACT OF RESUMPTION OR DISCONTINUATION OF ANTICOAGULANT TREATMENT. A population-based study.
    Gennaro N; Ferroni E; Zorzi M; Denas G; Pengo V
    Int J Cardiol; 2024 Jan; 394():131369. PubMed ID: 37722453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Prior Gastrointestinal Bleeding.
    Kwon S; Lee SR; Choi EK; Lee E; Jung JH; Han KD; Cha MJ; Oh S; Lip GYH
    Stroke; 2021 Jan; 52(2):511-520. PubMed ID: 33412904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risks and Benefits of Direct Oral Anticoagulants across the Spectrum of GFR among Incident and Prevalent Patients with Atrial Fibrillation.
    Shin JI; Secora A; Alexander GC; Inker LA; Coresh J; Chang AR; Grams ME
    Clin J Am Soc Nephrol; 2018 Aug; 13(8):1144-1152. PubMed ID: 30002224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study.
    Forslund T; Wettermark B; Andersen M; Hjemdahl P
    Europace; 2018 Mar; 20(3):420-428. PubMed ID: 28177459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-vitamin K antagonist oral anticoagulants versus warfarin in AF patients ≥ 85 years.
    Tsai CT; Liao JN; Chen SJ; Jiang YR; Chen TJ; Chao TF
    Eur J Clin Invest; 2021 Jun; 51(6):e13488. PubMed ID: 33420738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.